Skip to main content
  • Report an Adverse Event
  • Locate an MSL
RNAiScience logo
Search Menu
  • Home
  • Alnylam & RNAi
  • Congresses & Publications
  • Therapeutic Areas
  • Our Therapies
  • Pipeline & Clinical Trials
  • Connect With Us
  • Payer Connect
  • Log in
  • Sign Up
Alnylam logo
  • Privacy Policy
  • |
  • Terms of Use
| © 2025 Alnylam

This site is intended for US healthcare professionals.
© 2026 Alnylam Pharmaceuticals, Inc. All rights reserved.
MED-US-ALL-2400001

RNAiScience logo
  • Home
  • Alnylam & RNAi
  • Congresses & Publications
  • Therapeutic Areas
  • Our Therapies
  • Pipeline & Clinical Trials
  • Connect With Us
  • Payer Connect
Alnylam logo
  • Privacy Policy
  • |
  • Terms of Use

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

  • Report an Adverse Event
  • Locate an MSL
  • Log in
|
  • Sign Up

Search Results for "manifestation"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited. 

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

  • AMVUTTRA® (vutrisiran)
  • GIVLAARI® (givosiran)
  • ONPATTRO® (patisiran)
  • OXLUMO® (lumasiran)

Evidence of Fewer Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B This link is a pdf
Bookmark this pageBookmark this page

Characteristics of Patients Treated with Givosiran in ELEVATE, a Global Observational Longitudinal Registry of Patients with Acute Hepatic Porphyria This link is a pdf
Bookmark this pageBookmark this page

Characteristics of Patients Treated with Givosiran in ELEVATE, a Global Observational Longitudinal Registry of Patients with Acute Hepatic Porphyria This link is a pdf
Bookmark this pageBookmark this page

Impact of Vutrisiran on Activities of Daily Living and Functional Status in Patients with hATTR Amyloidosis This link is a pdf
Bookmark this pageBookmark this page

Baseline characteristics from BONAPH1DE: A global, observational, longitudinal study of patients with primary hyperoxaluria type 1 This link is a pdf
Bookmark this pageBookmark this page

Descriptive Analysis of Real-World Enrollment Data of Pediatric and Adult Patients From a Global Primary Hyperoxaluria Type 1 Registry (BONAPH1DE) This link is a pdf
Bookmark this pageBookmark this page

Real-world experience with therapeutics for ATTR in the Canadian population This link is a pdf
Bookmark this pageBookmark this page

The symptom and quality-of-life burden of Acute Hepatic Porphyria (AHP): Evidence from a systematic literature review This link is a pdf
Bookmark this pageBookmark this page

Amyloid-related imaging abnormalities in an ongoing Phase 1 study of mivelsiran, an investigational RNA interference therapeutic targeting amyloid precursor protein, in patients with Alzheimer’s disease This link is a pdf
Bookmark this pageBookmark this page

EXPLORE B post hoc analysis of chronic symptoms in patients with acute hepatic porphyria This link is a pdf
Bookmark this pageBookmark this page

NfL Levels Significantly Decrease in Response to Treatment with Patisiran or Vutrisiran in hATTR Amyloidosis with Polyneuropathy This link is a pdf
Bookmark this pageBookmark this page

Healthcare Resource Utilization and Costs Among Patient Segments with Acute Intermittent Porphyria: Analyses from a National Healthcare Database This link is a pdf
Bookmark this pageBookmark this page

Effect of RNAi Therapeutics Patisiran and Vutrisiran on Orthostatic Hypotension Due to Dysautonomia in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy This link is a pdf
Bookmark this pageBookmark this page

Final Results from a Phase 1/2, 48-Month, Open-Label Extension Study of Givosiran in Patients with Acute Intermittent Porphyria This link is a pdf
Bookmark this pageBookmark this page

Patient Experience with Acute Hepatic Porphyria Before and After Long-Term Givosiran Treatment: A Qualitative Interview Study This link is a pdf
Bookmark this pageBookmark this page

Effectiveness of Patisiran Following Switch From Tafamidis for the Treatment of Hereditary Transthyretin Mediated (hATTR) Amyloidosis with Polyneuropathy This link is a pdf
Bookmark this pageBookmark this page

HELIOS-A: Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin Mediated Amyloidosis with Polyneuropathy This link is a pdf
Bookmark this pageBookmark this page

Patient Experience with Acute Hepatic Porphyria Before and After Long-Term Givosiran Treatment: A Qualitative Interview Study This link is a pdf
Bookmark this pageBookmark this page

HELIOS-A: Impact of Vutrisiran on Quality of Life and Functional Status in Hereditary Transthyretin Mediated Amyloidosis with Polyneuropathy This link is a pdf
Bookmark this pageBookmark this page

Connecting the Musculoskeletal Dots to Identify the Early Manifestations of Transthyretin-Mediated (ATTR) Amyloidosis This link is a pdf
Bookmark this pageBookmark this page

History of Polyneuropathy and Musculoskeletal Manifestations in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy in APOLLO-B This link is a pdf
Bookmark this pageBookmark this page

The V122I Mutation in Hereditary Transthyretin-Mediated Amyloidosis is Significantly Associated with Polyneuropathy This link is a pdf
Bookmark this pageBookmark this page

ATTRv-PN Expert Opinion Slide Deck This link is a pdf
Bookmark this pageBookmark this page

Recommendations from a panel of experts for the diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States.

Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant External This link is a pdf
Bookmark this pageBookmark this page

V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.

Baseline Characteristics of Patients with Transthyretin Cardiac Amyloidosis Enrolled in the Patisiran Expanded Access Program This link is a pdf
Bookmark this pageBookmark this page

Pagination

  • View More Results

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

This site is intended for US healthcare professionals.
© 2026 Alnylam Pharmaceuticals, Inc. All rights reserved.
MED-US-ALL-2400001

  • Privacy Policy
  • |
  • Terms of Use
| © 2025 Alnylam
Alnylam logo
RNAI Logo

You are now leaving this site and being directed to a third-party website that is not maintained by Alnylam. Alnylam does not endorse and is not responsible for content or maintenance of third-party websites.

ContinueCancel

RNAI Logo

You are now leaving this site and being directed to another Alnylam website.

ContinueCancel

RNAI Logo

Intended for US healthcare professionals. This site is intended to provide balanced, evidence-based information to support scientific exchange. It is not intended to provide medical advice or recommendations for clinical practice.

Information about investigational therapeutics or investigational uses of approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.

Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.

Are you a healthcare professional practicing in the United States?

I confirm I am a US healthcare professional

I am a US payer or healthcare decision maker

I am not a US healthcare professional, or a US payer or healthcare decision maker

I am an Alnylam Team Member

X
Don't miss out!

Sign in to bookmark information and create your personal library

Log in

Don't have an account? Sign up